(INNS)
SAMROTAMAB VEDOTIN(INNC)
IMMUNOGLOBULIN G1-KAPPA, ANTI-[HOMO SAPIENS LRRC15 (LEUCINE-RICH REPEAT-CONTAINING PROTEIN 15, LEUCINE-RICH REPEAT INDUCED BY BETA-AMYLOID HOMOLOG, LIB)], HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY CONJUGATED TO AURISTATIN E; GAMMA1 HEAVY CHAIN (1-450) [HUMANIZED VH (HOMO SAPIENS IGHV1-2*02 (77.6%) -(IGHD) -IGHJ5*01 (86.7%)) [8.8.13] (1-120) -HOMO SAPIENS IGHG1*01 (CH1 (121- 218), HINGE (219-233), CH2 (234-343), CH3 (344-448), CHS (449-450)) (121-450)], (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN CHIMERIC (1'-214') [MUS MUSCULUS V-KAPPA (IGKV10-96*01 (85.30%) -IGKJ1*01 (91.7%)/HOMO SAPIENS IGKV1-39*01 (84.2%) -IGKJ4*01 (100%)) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01,KM3 A45.1 (153), V101 (191)(108'-214')]; DIMER (229-229'':232-232'')-BISDISULFIDE; CONJUGATED, ON AN AVERAGE OF 2 CYSTEINYL, TO MONOMETHYLAURISTATIN E (MMAE), VIA A CLEAVABLE MALEIMIDOCAPROYL-VALYL-CITRULLINYL-P-AMINOBENZYLOXYCARBONYL (MC-VAL-CIT-PABC) TYPE LINKER. RECOMMENDED INN: LIST 80(WHO)
SAMROTAMABUM VEDOTINUM(INN)